Posts Tagged ‘Gadolinium’

Gadolinium, Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy – Article Index
Below is a collection of Gadolinium, Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic  Fibrosing Dermopathy (NFD) articles provided to you by Schmidt & Clark, LLP. Please remember that if you or a loved one have developed NSF or NFD after having received an injection of a gadolinium-based contrast [...]

Prohance (gadoteridol), a gadolinium-based contrast agent which is commonly used to improve the visibility of internal structures when patients undergo an MRI has been linked to a serious, life-threatening disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
If you or a loved one have had an MRI or MRA, and since developed [...]

OptiMARK (gadoversetamide), a gadolinium-based contrast agent which is commonly used to improve the visibility of internal structures when patients undergo an MRI has been linked to a serious, life-threatening disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
If you or a loved one have had an MRI or MRA, and since developed [...]

Omniscan (gadodiamide), a gadolinium-based contrast agent which is commonly used to improve the visibility of internal structures when patients undergo an MRI has been linked to a serious, life-threatening disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
If you or a loved one have had an MRI or MRA, and since developed [...]

A lawsuit was recently filed in US District Court by a former nurse charging that Omniscan was responsible for causing her to develop a serious skin and joint condition called Nephrogenic Systemic Fibrosis. This may be the first lawsuit filed against GE Healthcare, the manufacturer of Omniscan, as a result of adverse events related to [...]

ProHance is a MRI contrast agent manufactured by Bracco Diagnostics. It received approval from the US Food and Drug Administration in 1992 and was released to the retail market later that year. ProHance is used to enhance the images obtained by MRI procedures and is used to detail any abnormal tissue in the brain, spine, [...]

OptiMARK is a Gadolinium based contrast agent used to enhance the images obtained by MRI procedures. Also known as Gadoversetamide, the agent is manufactured by Mallinckrodt, which is a division of Tyco Healthcare. OptiMARK is considered a paramagnetic MRI contrast agent and is used to increase the detail of MRI images of the brain, spine, [...]

Omniscan was created as a contrast agent for use in Magnetic Resonance Imaging (MRI) procedures and was approved for use by the US Food and Drug Administration in 1993. Also known as Gadodiamide, the agent is considered a paramagnetic agent that tends to generate a localized magnetic field. When protons move through this field, the [...]

MultiHance is manufactured by Bracco Diagnostics based out of Princeton, New Jersey. Also known as Gadobenate dimeglumine, the contrast agent was approved by the US Food and Drug Administration for use in enhancing MRI images on November 23, 2004. MultiHance is considered a paramagnetic MRI contrast agent meaning that it tends to follow magnetic fields [...]

MultiHance (gadobenate dimeglumine), a gadolinium-based contrast agent which is commonly used to improve the visibility of internal structures when patients undergo an MRI has been linked to a serious, life-threatening disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
If you or a loved one have had an MRI or MRA, and since [...]

The first cases of Nephrogenic Systemic Fibrosis were discovered in 1997 with the first medical references detailing the condition written in 2000. The condition only affects individuals with impaired renal function or renal failure and causes the skin and connective tissues in the body to thicken and harden. The typical symptoms of Nephrogenic Systemic Fibrosis [...]

Magnevist was the first Gadolinium based contrast agent approved for use in the United States by the US Food and Drug Administration. Introduced in 1988, the contrast agent has been used in more than 80 million applications worldwide. As the first contrast agent approved for use in enhancing MRI images, Magnevist is still considered an [...]

Magnevist (gadopentetate dimeglumine), a gadolinium-based contrast agent which is commonly used to improve the visibility of internal structures when patients undergo an MRI has been linked to a serious, life-threatening disease known as Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
If you or a loved one have had an MRI or MRA, and since [...]

A study was recently conducted to determine the risk of developing Nephrogenic Systemic Fibrosis (NSF) in patients with advanced kidney disease who had undergone an MRI using a Gadolinium based contrast agent. The study determined that for each MRI procedure using a Gadolinium based contrast agent that the patient undergoes, the risk of developing a [...]

The US Food and Drug Administration recently issued an alert to the healthcare community warning of an increased risk of the development of Nephrogenic Systemic Fibrosis in patients with impaired renal function or renal failure who have received a Gadolinium based contrast agent prior to an MRI procedure. The alert, which was issued in December [...]

Nephrogenic systemic fibrosis (NSF) is an extremely rare condition that occurs in some individuals enduring an advanced stage of kidney disease. Also known as nephrogenic fibrosing dermopathy (NFD), the first cases of the condition were documented in 1997. Since then, less that 300 cases have been confirmed worldwide. Researchers are unsure what causes the condition, [...]

Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), is a rare condition characterized by the tightening and stiffening of the skin on the extremities. The condition is exclusive to patients in moderate to late stage kidney disease and affects men and women of every age and nationality. There are no confirmed cases [...]

Until recently, it was believed that MRI contrast agents were some of the safest solutions used on humans. Very few side effects and adverse reactions were reported and many of those issues were very mild. Then, in 2006 researchers discovered a plausible link between the use of Gadolinium based MRI contrast agents and the development [...]

In 2006, reports began to emerging linking the usage of Gadolinium based contrast agents to the development of a rare condition called Nephrogenic Systemic Fibrosis. The condition was first noted in patients undergoing dialysis who had recently received an injection of a contrast agent containing Gadolinium prior to an MRI or MRA procedure. While the [...]

The US Food and Drug Administration has recently become aware of a number of cases of Nephrogenic Systemic Fibrosis occurring in some individuals with advanced kidney disease and kidney failure. These individuals had recently undergone an MRI or MRA procedure using a Gadolinium based MRI contrast agent to enhance the images obtained the procedure. There [...]

Nephrogenic Systemic Fibrosis is a condition that causes the skin on the extremities to become thick and harden, causing debilitation, severe pain, and disfiguring the person that it affects. The condition only occurs in patients with advanced kidney disease or kidney failure and then, only after they have been exposed to a Gadolinium based contrast [...]

In 2006, a report was released detailing a rare condition affecting a small number of individuals suffering from kidney damage and kidney failure. The condition was called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD) and was considered potentially life threatening. All of the patients detailed in the report had received a Gadolinium based [...]

Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, is a debilitating disorder affecting the skin. The condition affects both men and women of every age, from infants to the elderly, but typically occurs in individuals that are middle aged. The condition can affect individuals of every ethnicity and has been found mainly in Europe, [...]

A public health advisory was recently issued by the US Food and Drug Administration warning about a severe disorder associated with advanced kidney disease and the use of gadolinium based contrast agents used during magnetic resonance imaging (MRI). As of December 2006, the agency had received over 90 reports of patients suffering from advance kidney [...]

Gadolinium is considered a paramagnetic metal ion, a substance that is known to move into magnetic fields. It is this property that makes Gadolinium so useful in Magnetic Resonance Imaging (MRI) and was approved for this use by the US Food and Drug Administration (FDA) in 1988. The substance is used as a contrast agent, [...]